{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,24]],"date-time":"2026-03-24T11:56:03Z","timestamp":1774353363848,"version":"3.50.1"},"reference-count":10,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2021,9,26]]},"DOI":"10.7759\/cureus.18291","type":"journal-article","created":{"date-parts":[[2021,9,26]],"date-time":"2021-09-26T10:53:08Z","timestamp":1632653588000},"source":"Crossref","is-referenced-by-count":7,"title":["Axonal-Variant Guillian-Barre Syndrome Temporally Associated With mRNA-Based Moderna SARS-CoV-2 Vaccine"],"prefix":"10.7759","author":[{"given":"Vikas","family":"Dalwadi","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Diana","family":"Hancock","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ahmad A","family":"Ballout","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anthony","family":"Geraci","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.7861\/clinmedicine.10-4-399","article-title":"Guillain-Barr\u00e9 syndrome","volume":"10","author":"Pritchard J","year":"2010","unstructured":"Pritchard J. Guillain-Barr\u00e9 syndrome. Clin Med (Lond). 2010, 10:399-401. 10.7861\/clinmedicine.10-4-399","journal-title":"Clin Med (Lond)"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1093\/brain\/awaa433","article-title":"Epidemiological and cohort study finds no association between COVID-19 and Guillain-Barr\u00e9 syndrome","volume":"144","author":"Keddie S","year":"2021","unstructured":"Keddie S, Pakpoor J, Mousele C, et al.. Epidemiological and cohort study finds no association between COVID-19 and Guillain-Barr\u00e9 syndrome. Brain. 2021, 144:682-93. 10.1093\/brain\/awaa433","journal-title":"Brain"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1097\/CND.0b013e31824db14e","article-title":"Guillain-Barr\u00e9 syndrome after influenza vaccination in the United States, a report from the CDC\/FDA vaccine adverse event reporting system (1990-2009)","volume":"14","author":"Souayah N","year":"2012","unstructured":"Souayah N, Yacoub HA, Khan HM, et al.. Guillain-Barr\u00e9 syndrome after influenza vaccination in the United States, a report from the CDC\/FDA vaccine adverse event reporting system (1990-2009). J Clin Neuromuscul Dis. 2012, 14:66-71. 10.1097\/CND.0b013e31824db14e","journal-title":"J Clin Neuromuscul Dis"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2034201","article-title":"Interim results of a phase 1-2a trial of Ad26.COV2.S Covid-19 vaccine","volume":"384","author":"Sadoff J","year":"2021","unstructured":"Sadoff J, Le Gars M, Shukarev G, et al.. Interim results of a phase 1-2a trial of Ad26.COV2.S Covid-19 vaccine. N Engl J Med. 2021, 384:1824-35. 10.1056\/NEJMoa2034201","journal-title":"N Engl J Med"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2035389","article-title":"Efficacy and safety of the mRNA-1273 SARS-CoV-2 vaccine","volume":"384","author":"Baden LR","year":"2021","unstructured":"Baden LR, El Sahly HM, Essink B, et al.. Efficacy and safety of the mRNA-1273 SARS-CoV-2 vaccine. N Engl J Med. 2021, 384:403-16. 10.1056\/NEJMoa2035389","journal-title":"N Engl J Med"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(20)32661-1","article-title":"Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK","volume":"397","author":"Voysey M","year":"2021","unstructured":"Voysey M, Clemens SA, Madhi SA, et al.. Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK. Lancet. 2021, 397:99-111. 10.1016\/S0140-6736(20)32661-1","journal-title":"Lancet"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2034577","article-title":"Safety and efficacy of the BNT162b2 mRNA Covid-19 vaccine","volume":"383","author":"Polack FP","year":"2020","unstructured":"Polack FP, Thomas SJ, Kitchin N, et al.. Safety and efficacy of the BNT162b2 mRNA Covid-19 vaccine. N Engl J Med. 2020, 383:2603-15. 10.1056\/NEJMoa2034577","journal-title":"N Engl J Med"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.7759\/cureus.13426","article-title":"Neurological cmplications of COVID-19: Guillain-Barre syndrome following Pfizer COVID-19 vaccine","volume":"13","author":"Waheed S","year":"2021","unstructured":"Waheed S, Bayas A, Hindi F, Rizvi Z, Espinosa PS. Neurological cmplications of COVID-19: Guillain-Barre syndrome following Pfizer COVID-19 vaccine. Cureus. 2021, 13:e13426. 10.7759\/cureus.13426","journal-title":"Cureus"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1155\/2021\/3619131","article-title":"Exacerbating Guillain-Barr\u00e9 syndrome eight days after vector-based COVID-19 vaccination","volume":"2021","author":"Finsterer J","year":"2021","unstructured":"Finsterer J. Exacerbating Guillain-Barr\u00e9 syndrome eight days after vector-based COVID-19 vaccination. Case Rep Infect Dis. 2021, 2021:3619131. 10.1155\/2021\/3619131","journal-title":"Case Rep Infect Dis"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1007\/s00415-020-09742-2","article-title":"Axonal variants of Guillain-Barr\u00e9 syndrome: an update","volume":"268","author":"Shang P","year":"2021","unstructured":"Shang P, Zhu M, Wang Y, et al.. Axonal variants of Guillain-Barr\u00e9 syndrome: an update. J Neurol. 2021, 268:2402-19. 10.1007\/s00415-020-09742-2","journal-title":"J Neurol"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/72393-axonal-variant-guillian-barre-syndrome-temporally-associated-with-mrna-based-moderna-sars-cov-2-vaccine","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,2,9]],"date-time":"2024-02-09T19:34:12Z","timestamp":1707507252000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/72393-axonal-variant-guillian-barre-syndrome-temporally-associated-with-mrna-based-moderna-sars-cov-2-vaccine"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,9,26]]},"references-count":10,"URL":"https:\/\/doi.org\/10.7759\/cureus.18291","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2021,9,26]]}}}